Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Watch this piece of work

<< Previous

Bullboard Posts

Next >>

Comment by Captainblkon Mar 01, 2021 8:28pm

267 Views

Post# 32691806

RE:Watch this piece of work

Dude51 wrote:

15:59:48 V 0.07 0.005 5,000 1 Anonymous 1 Anonymous K

yea i saw that one on ceo.ca. here is hoping that living in a psot GME short world we have a more aware and scrutinzing type of retail investor floating around.

seeing all these bashers seep out of the dirt having never posted on this board before, as well as the dummy trade really goes to show you some of the lengths ppl go to mess with the money.

here is hoping the momentum continues short term as well as over the next month because I could see this realistically growing to 0.25 soon I may take my inital investment out by then and ride on house money

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Jan. 10, 2025)